Pulmozyme Access Solutions—we focus on access so you can focus on
Pulmozyme Access Solutions is committed to helping patients access
our medicines, regardless of their ability to pay
Genentech Access Solutions offers a range of access and
reimbursement support for your patients and practice.
Find the right patient assistance option for your patients using the Patient Assistance Tool
To speak with one of our dedicated Specialists, call
Is your patient insured?
Does your patient have commercial insurance?What does this mean?
Has your patient already been referred to the Pulmozyme Co-pay Card Program and is either ineligible or no longer receiving assistance?
Has your patient already been referred to an independent co-pay assistance foundation and is either ineligible or no longer receiving assistance?
Is the patient using Pulmozyme for an FDA-approved indication?
Is the patient 18 years of age or older, or have a legal guardian over the age of 18?
Is the patient’s co-pay over $30 per month?
Your Patient Might Qualify for a Referral to the Pulmozyme Co-pay Card Program
If eligible commercially insured patients need assistance with their out-of-pocket costs, Pulmozyme Access Solutions can refer them to the Pulmozyme Co-pay Card Program.*
*In order to be eligible for the Pulmozyme Co-pay Card Program, the patient must have commercial insurance, must not have Medicare, Medicaid or other government insurance, and must meet other eligibility criteria. They also must agree to the rules set forth in the terms and conditions for the program. Please visit www.PulmozymeCopayCard.com for the full list of terms and conditions.
Your Patient Might Qualify for a Referral to an Independent Co-pay Assistance Foundation
For eligible patients with commercial or public health insurance, Pulmozyme Access Solutions offers referrals to independent co-pay assistance foundations.*
*Genentech does not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Pulmozyme Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech’s endorsement or financial support. There may be other foundations to support the patient's disease state.
Your Patient Might Qualify for a Referral to the Genentech® Access to Care Foundation (GATCF)
GATCF helps eligible patients who meet specific criteria receive their Genentech medicine free of charge.*
*To be eligible for free Genentech medicine from GATCF, insured patients must have exhausted all other forms of patient assistance (including the Pulmozyme Co-pay Card Program and support from independent co-pay assistance foundations) and meet financial criteria. Uninsured patients must meet different financial criteria.
Reliable, Effective Access and Reimbursement Services
*In order to be eligible for the Pulmozyme Co-pay Card, the patient must confirm that they meet the eligibility criteria and agree to the rules set forth in the terms and conditions for the program. Please visit https://www.genentech-access.com/hcp/brands/pulmozyme/find-patient-assistance/co-pay-assistance-foundations.html for the full list of terms and conditions.
†Genentech does not influence or control the operations or eligibility criteria of any independent co-pay assistance foundation and cannot guarantee co-pay assistance after a referral from Genentech Access Solutions. The foundations to which we refer patients are not exhaustive or indicative of Genentech's endorsement or financial support. There may be other foundations to support the patient's disease state.
Important Safety Information & Indication
Pulmozyme (dornase alfa) is indicated for daily administration in conjunction with standard therapies for the management of cystic fibrosis (CF) patients to improve pulmonary function.
In CF patients with an FVC ≥ 40% of predicted, daily administration of Pulmozyme has also been shown to reduce the risk of respiratory tract infections requiring parenteral antibiotics.
Pulmozyme is contraindicated in patients with known hypersensitivity to dornase alfa, Chinese Hamster Ovary cell products, or any component of the product.
The most common adverse reactions associated with the use of Pulmozyme include: voice alteration, pharyngitis, rash, laryngitis, chest pain, conjunctivitis, rhinitis, decrease in FVC of ≥ 10%, fever, dyspepsia, and dyspnea. There have been no reports of anaphylaxis attributed to the administration of Pulmozyme. Mild to moderate urticaria and mild skin rash have been observed and have been transient.
The safety and effectiveness of Pulmozyme have been established in pediatric patients 5 years of age and older. The safety of Pulmozyme, 2.5 mg by inhalation, was studied with 2 weeks of daily administration in 65 patients with cystic fibrosis aged 3 months to < 5 years. While clinical trial data are limited in pediatric patients younger than 5 years of age, the use of Pulmozyme should be considered for pediatric CF patients who may experience potential benefit in pulmonary function or who may be at risk of respiratory tract infection.
The safety of Pulmozyme, 2.5 mg by inhalation, was studied with 2 weeks of daily administration in 98 pediatric patients with cystic fibrosis 3 months to 10 years of age (65 aged 3 months to < 5 years, 33 aged 5 to ≤ 10 years). The PARI BABY™ reusable nebulizer (which uses a facemask instead of a mouthpiece) was utilized in patients unable to demonstrate the ability to inhale or exhale orally throughout the entire treatment period (54/65, 83% of the younger; and 2/33, 6% of the older patients). Overall, the nature of adverse reactions was similar to that seen in the placebo-controlled trials in older patients. The number of patients reporting cough was higher in the younger age group as compared to the older age group (29/65, 45%; compared to 10/33, 30%) as was the number reporting moderate to severe cough (24/65, 37%; compared to 6/33, 18%). The number of patients reporting rhinitis was higher in the younger age group as compared to the older age group (23/65, 35%; compared to 9/33, 27%) as was the number reporting rash (4/65, 6% as compared to 0/33, 0%).